Sinocelltech Group - Public Comps and Valuation Multiples

Sinocelltech Group Overview

About Sinocelltech Group

Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.

Founded

2007

HQ

Employees

n/a

Website

sinocelltech.com

Sectors

Biopharmaceuticals
Vaccines & Immunotherapies
BioTech

Financials

Last FY Revenue $359M

Last FY EBITDA $53.3M

EV

$3.4B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Sinocelltech Group Financials

See Sinocelltech Group valuation multiples based on analyst estimates

Sinocelltech Group P&L

In the most recent fiscal year, Sinocelltech Group reported revenue of $359M and EBITDA of $53.3M.

Sinocelltech Group expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Sinocelltech Group valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	$359M	XXX	XXX	XXX
Gross Profit	XXX	$344M	XXX	XXX	XXX
Gross Margin	XXX	96%	XXX	XXX	XXX
EBITDA	XXX	$53.3M	XXX	XXX	XXX
EBITDA Margin	XXX	15%	XXX	XXX	XXX
EBIT	XXX	$97.0M	XXX	XXX	XXX
EBIT Margin	XXX	27%	XXX	XXX	XXX
Net Profit	XXX	$16.0M	XXX	XXX	XXX
Net Margin	XXX	4%	XXX	XXX	XXX
Net Debt	XXX	$236M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Sinocelltech Group including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Sinocelltech Group achieved $359M in revenue and $53.3M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	$359M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$344M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	95.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$53.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	14.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$97.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	27.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$16.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	4.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$236M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Sinocelltech Group

This financial data table provides comprehensive performance metrics for Sinocelltech Group, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Sinocelltech Group reported $359M in total revenue.
Fiscal year EBITDA was $53.3M.
The company maintained a gross profit margin of 95.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 14.8%.
Net profit margin reached 4.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Sinocelltech Group. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Sinocelltech Group Stock Performance

Sinocelltech Group has current market cap of CNY 21.0B (or $3.0B), and EV of CNY 23.7B (or $3.4B).

Market Cap Evolution

Sinocelltech Group Stock Data

As of January 16, 2026, Sinocelltech Group's stock price is CNY 47 (or $7).

See Sinocelltech Group trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.4B	$3.0B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Sinocelltech Group Valuation Multiples

Sinocelltech Group's trades at 9.4x EV/Revenue multiple, and 63.5x EV/EBITDA.

See valuation multiples for Sinocelltech Group and 15K+ public comps

Sinocelltech Group Financial Valuation Multiples

As of January 16, 2026, Sinocelltech Group has market cap of $3.0B and EV of $3.4B.

Equity research analysts estimate Sinocelltech Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sinocelltech Group's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$3.0B	XXX	$3.0B	XXX	XXX	XXX
EV (current)	$3.4B	XXX	$3.4B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	9.4x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	63.5x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	34.9x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	187.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-94.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sinocelltech Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Sinocelltech Group Margins & Growth Rates

Sinocelltech Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Sinocelltech Group's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sinocelltech Group's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Sinocelltech Group and other 15K+ public comps

Sinocelltech Group Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	15%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	36%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	69%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial